K Pharma,Inc.
Stock Price Chart
2026/08/19 UpdatedPrice Trend
2026/08/19 UpdatedPrice & Trading Details
2026/08/19 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | |
|---|---|
| Income Statement | |
| Revenue | ¥1,000M |
| Gross Profit | ¥910M |
| Operating Income | ¥366M |
| Pretax Income | ¥366M |
| Net Income | ¥260M |
| EPS | ¥23.07 |
| Operating Margin | 36.61% |
| Balance Sheet | |
| Total Assets | ¥3,314M |
| Total Equity | ¥3,105M |
| Total Liabilities | ¥209M |
| Cash | ¥3,266M |
| Interest-bearing Debt | - |
| Equity Ratio | 93.69% |
| D/E Ratio | 0.00 |
| Cash Flow | |
| Operating CF | ¥454M |
| Investing CF | -¥11M |
| Financing CF | ¥1,486M |
| Free CF | ¥445M |
| Efficiency | |
| ROE | 8.38% |
| ROA | 7.86% |
Latest IR Information
-
Financial Summary for the Six Months Ended December 2026
Provides an overview of the interim results for the 2026 fiscal year, progress on the iPS drug discovery business, and discusses segments, outlook, and capital policy/dividend policy, which are not yet disclosed.
Read more -
Financial Summary for the Second Quarter of the Fiscal Year Ending December 2026 (Interim) [Japanese GAAP] (Consolidated)
Disclosure of the results for the second quarter (mid-year) of the fiscal year ending December 2026. Highlights sales, operating income, ordinary income, net income, and the financial position. The balance sheet includes details of current assets, fixed assets, liabilities, capital...
Read more
Latest News (5 items)
Company Information
About
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is headquartered in Minato, Japan.
